Bumper Offer - Urjas oil Just @ Rs. 1
Zipod 200 Mg Tablet is a prescription drug, available for use as Tablet. It is typically used for the treatment of Urinary Tract Infection, Bronchitis. Zipod 200 Mg Tablet also has some secondary and off-label uses. These are listed below.
The optimal dosage of Zipod 200 Mg Tablet is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. Detailed information has been provided in the dosage section.
Some other side effects of Zipod 200 Mg Tablet have been listed ahead. Normally, these side effects of Zipod 200 Mg Tablet are not long lasting and go away when the treatment is finished. However, if these continue for a longer time, consult your doctor right away.
In addition, Zipod 200 Mg Tablet's effect is Mild during pregnancy and Moderate for lactating mothers. In addition, Zipod 200 Mg Tablet's effects on the liver, heart and kidney are discussed below in the Zipod 200 Mg Tablet related warnings section.
Other conditions have been mentioned below in the Zipod 200 Mg Tablet contraindications section.
Drug reaction of Zipod 200 Mg Tablet with other medicines has been reported. A complete list of these interactions is given below.
You should also be aware that Zipod 200 Mg Tablet is safe while driving, and is addiction.
Zipod 200 Mg Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| 13 - 18 years (Adolescent) |
|
| Geriatric |
|
| 2 - 12 years (Child) |
|
| Infant (1 month to 2 years) |
|
Based on research, the following side effects have been observed when Zipod 200 Mg Tablet is used -
Moderate
Mild
Is the use of Zipod 200 Mg Tablet safe for pregnant women?
Zipod rarely shows harmful effects in in pregnant ladies. Even if it does, the effects are mild
Is the use of Zipod 200 Mg Tablet safe during breastfeeding?
Zipod can cause moderate side effects on breastfeeding women. If you feel its side effects, then stop taking this drug and consult your doctor. Take this medicine again only if your doctor advises to do so.
What is the effect of Zipod 200 Mg Tablet on the Kidneys?
There may be some adverse effects on kidney after taking Zipod. If you observe any such side effects, stop taking this drug. Consume this medicine again only if your doctor advises you to do so.
What is the effect of Zipod 200 Mg Tablet on the Liver?
There may be an adverse effect on the liver after taking Zipod. If you observe any side effects on your body then stop taking this drug. Take this medicine again only if your doctor advises you to do so.
What is the effect of Zipod 200 Mg Tablet on the Heart?
Zipod may have mild side effects on the heart. Most people will never see any effect on the heart.
Zipod 200 Mg Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Zipod 200 Mg Tablet unless your doctor advises you to do so -
Is this Zipod 200 Mg Tablet habit forming or addictive?
No, there is no any evidence that Zipod 200 Mg Tablet is addictive.
Is it safe to drive or operate heavy machinery when consuming?
Yes, it is safe to do these activities or work after taking Zipod 200 Mg Tablet as it does not make you drowsy.
Is it safe?
Yes, Zipod 200 Mg Tablet does not show any kind of adverse effect.
Is it able to treat mental disorders?
No, Zipod 200 Mg Tablet cannot treat any kind of mental disorder.
Interaction between Food and Zipod 200 Mg Tablet
You can take Zipod 200 Mg Tablet with food.
Interaction between Alcohol and Zipod 200 Mg Tablet
Information about the interaction of Zipod 200 Mg Tablet and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vantin® (cefpodoxime proxetil )
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vantin® (cefpodoxime proxetil )
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vantin® (cefpodoxime proxetil )
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vantin® (cefpodoxime proxetil )
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vantin® (cefpodoxime proxetil )
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311
